Form 4: Zevra Therapeutics Director Douglas Calder Granted 30,000 Stock Options as Compensation

Zevra Therapeutics, Inc. director Douglas W. Calder was granted 30,000 stock options as compensation for his board service, aligning his interests with shareholders.

Summary

• Douglas W. Calder, a Director of ZEVRA THERAPEUTICS, INC. (ZVRA), was granted 30,000 stock options.
• The options have an exercise price of $8.62, which was the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the grant date.
• The grant date for these options was May 29, 2025.
• The options were awarded as compensation for Mr. Calder's service on the Issuer's board of directors, in accordance with the company's tenth amended and restated non-employee director compensation policy.
• The options will vest 100% on the earliest of: (i) the first anniversary of the grant date, (ii) one day prior to the first annual stockholders meeting after the grant date, or (iii) immediately prior to a change in control of the Issuer, subject to continued service.
• The expiration date for these stock options is May 28, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine compensation grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. There are no unexpected positive or negative financial outcomes reported.

Positives

• The grant of stock options to Director Douglas W. Calder aligns his financial interests directly with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• This compensation is part of a pre-existing, publicly disclosed non-employee director compensation policy, indicating a structured approach to governance.

Risks

• The value of the stock options is subject to market fluctuations, meaning the actual realized value for the director could be lower than the exercise price if the stock price declines.
• The vesting conditions require continued service, which could be a risk for the director if their service is terminated before vesting.

Future Outlook

The stock options are subject to a vesting schedule, with 100% vesting on the earlier of the first anniversary of the grant date, one day prior to the first annual stockholders meeting after the grant date, or immediately prior to a change in control, contingent on continued service. This indicates a future alignment of the director's incentives with long-term company performance.

Management Comments

• The grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and pharmaceuticals, to attract and retain experienced board members and align their interests with long-term shareholder value creation. This practice is a standard component of corporate governance and executive compensation frameworks.

Comparison to Industry Standards

• The practice of granting stock options as compensation for non-employee directors is a widely accepted industry standard, comparable to practices at companies like Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD), which also utilize equity-based compensation to incentivize board members.
• The vesting schedule, tying full vesting to either a one-year anniversary, the next annual meeting, or a change of control, is typical for director equity grants, ensuring continued commitment while providing liquidity events.
• The exercise price being equal to the closing market price on the grant date is standard for "at-the-money" options, which are common for director compensation.

Corporate Governance

Related Party Transactions

• The grant of 30,000 stock options to Douglas W. Calder, a director of Zevra Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. It is a standard form of non-cash compensation.

Next Steps

• The stock options will vest according to the specified schedule, contingent on Douglas W. Calder's continued service on the board.

Key Dates

Keywords

ZEVRA THERAPEUTICS, ZVRA, Douglas W. Calder, stock options, director compensation, insider transaction, Form 4, equity compensation, corporate governance